Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.
Advertisement
Set Alert for Articles By John Davis

Latest From John Davis

Sanofi To Co-Develop Digital Therapeutic For MS Patients

Sanofi's latest digital health move will see it collaborating with Happify Health on a digital therapeutic for patients with multiple sclerosis, a therapeutic area it knows well.

 

Digital Health Deals

Pipeline Watch: Phase III Starts With Evobrutinib, Gaboxadol

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Pipeline Watch

Brineura Cleared By England's NICE For Ultra-Rare Batten Disease

NICE has recommended BioMarin’s Brineura for use in the National Health Service in England after a managed access deal and product pricing were agreed between BioMarin and NHS England. Final details of the deal are expected next month.

 

 

Health Technology Assessment Neurology

BioMarin's Brineura Pricing Deal Allows UK Market Access

More than two years after EU approval, BioMarin and the National Health Service have agreed pricing for the ultra-rare disease therapy, Brineura, allowing it to be publicly funded while further clinical data are collected as part of a managed access agreement.

 

Neurology Market Access

AstraZeneca's Imfinzi Sees Benefits In CASPIAN Study

Further details of Imfinzi’s benefits in small cell lung cancer, an aggressive and poorly treated tumor, from the interim analysis of the CASPIAN Phase III study, show statistically significant and clinically meaningful activity.

ImmunoOncology Clinical Trials

Pipeline Watch: Phase III Readouts For Tenapanor, Ofatumumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All
Advertisement
UsernamePublicRestriction

Register